0001683168-18-000770.txt : 20180328 0001683168-18-000770.hdr.sgml : 20180328 20180328080110 ACCESSION NUMBER: 0001683168-18-000770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170714 FILED AS OF DATE: 20180328 DATE AS OF CHANGE: 20180328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dowling Joseph D CENTRAL INDEX KEY: 0001611860 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-54677 FILM NUMBER: 18717043 MAIL ADDRESS: STREET 1: 591 CAMINO DE LA REINA, STE 1200 CITY: SAN DIEGO STATE: CA ZIP: 92108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CV Sciences, Inc. CENTRAL INDEX KEY: 0001510964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 800944970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2688 SOUTH RAINBOW AVENUE, SUITE B CITY: LAS VEGAS STATE: NV ZIP: 89146 BUSINESS PHONE: 866-290-2157 MAIL ADDRESS: STREET 1: 2688 SOUTH RAINBOW AVENUE, SUITE B CITY: LAS VEGAS STATE: NV ZIP: 89146 FORMER COMPANY: FORMER CONFORMED NAME: CannaVEST Corp. DATE OF NAME CHANGE: 20130205 FORMER COMPANY: FORMER CONFORMED NAME: Foreclosure Solutions, Inc. DATE OF NAME CHANGE: 20110124 4 1 dowling_f4.xml OWNERSHIP DOCUMENT X0306 4 2017-07-14 0 0001510964 CV Sciences, Inc. CVSI 0001611860 Dowling Joseph D 2688 S. RAINBOW BLVD., SUITE B LAS VEGAS NV 89146 0 1 0 0 CFO, Secretary Employee Stock Option (right to buy) 0.368 2017-07-14 4 A 0 250000 0 A 2017-07-14 2026-07-05 Common Stock 250000 250000 D Employee Stock Option (right to buy) 0.365 2017-07-14 4 A 0 250000 0 A 2017-07-14 2027-04-06 Common Stock 250000 250000 D On July 6, 2016, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) the first time the Issuer completes development of a U.S. Food & Drug Administration ("FDA") current good manufacturing practice grade batch of successfully synthetically formulated Cannabidiol ("CBD") for use in drug development activities (25% vesting of the shares subject to the option); (ii) when the Company has final meeting minutes from a pre-investigational new drug application ("IND") meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (iii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iv) when the Company commences its first human dosing under the IND (25% vesting of the shares subject to the option). On July 14, 2017, the second performance criterion was met resulting in vesting of the option as to 250,000 shares. On April 7, 2017, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) when the Company has final meeting minutes from a pre-IND meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (ii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iii) when the Company commences its first human dosing under the IND (50% vesting of the shares subject to the option). On July 14, 2017, the first performance criterion was met resulting in vesting of the option as to 250,000 shares. /s/ Joseph Dowling 2018-03-27